Origin of Enasidenib 60 tablets

Enasidenib (Enasidenib) It was developed by Agios Pharmaceuticals and licensed to Celgene for further development. Ensidipine is an inhibitor of the isocitrate dehydrogenase-2 (IDH2) enzyme and is available as a mesylate salt, available orally as a 50 mg tablet (equivalent to 60 mg mesylate Enasidenib) and as a 100 mg tablet (equivalent to 120 mg mesylate Enasidenib).

Ensidipine is an oral targeted treatment for acute myeloid leukemia (AML) that works by blocking isocitrate dehydrogenase 2 (IDH2). Blocking IDH2 helps young red blood cells (blasts) in the bone marrow mature into healthy, functioning red blood cells, white blood cells and platelets. These cells are necessary in our bodies to deliver oxygen to tissues, help fight infection, and prevent bleeding. When deciding to use a drug, the risks and benefits of taking the drug must be weighed, and this is a decision that patients and doctors will make.

Ensiidi plain investigational medicine is not currently on the market in the country, nor is it covered by medical insurance. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic encidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*60 tablets produced by a Bangladesh pharmaceutical factory may be around 4,000 yuan per box (the price may fluctuate due to exchange rates). Its drug ingredients are basically the same as those of the original encidipine generic drug.